TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

Novo Nordisk

NVO
MetabolicOncologyCardiovascular
Big Pharma

Danish pharma dominating diabetes and obesity markets with Ozempic, Wegovy, and insulin portfolio. World leader in GLP-1 therapies.

$35.7B
Revenue (2024)
$420.0B
Market Cap
-
Trials
42
Approved (2yr)

Key Drugs

XULTOPHY 100/3.6
insulin degludec
Metabolic
GLP-1R 2 indications · 2016
FIASP PENFILL
insulin aspart
Metabolic
Insulin receptor 1 indications · 2017
FIASP
insulin aspart
Metabolic
Insulin receptor 1 indications · 2017
FIASP FLEXTOUCH
insulin aspart
Metabolic
Insulin receptor 1 indications · 2017
SAXENDA
liraglutide
GLP-1R 3 indications · 2014

Recent Activity

WEGOVY 2026-02-25
Labeling
SAXENDA 2026-02-25
Labeling
WEGOVY 2026-02-25
Labeling
RYBELSUS 2026-01-30
Labeling
WEGOVY 2026-01-29
Labeling
WEGOVY 2026-01-29
Labeling
WEGOVY 2025-12-22
Type 3 - New Dosage Form
WEGOVY 2025-11-21
Efficacy
RYBELSUS 2025-10-17
Labeling
RYBELSUS 2025-10-17
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 88%
8 drugs Phase 3: 113 Phase 2: 25 Phase 1: 150
Oncology 5%
0 drugs Phase 3: 7 Phase 2: 4 Phase 1: 7
Cardiovascular 3%
0 drugs Phase 3: 4 Phase 2: 2 Phase 1: 6
Infectious Disease 2%
0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 6
Neurology 2%
0 drugs Phase 3: 3 Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
AZURITY specialty
Cardiovascular, Oncology, Neurology, Metabolic, Infectious Disease
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology